Is Matrix Metalloproteinase-9 Associated with Post-Stroke Cognitive Impairment or Dementia?

被引:7
作者
Zhao, Jianhua [1 ]
Yang, Fangli [1 ]
Peng, Xue [2 ]
Li, Qing [1 ]
Wang, Fan [1 ]
Xu, Zhixiu [1 ]
Cai, Ruiyan [1 ]
Ji, Danxia [3 ]
Zhang, Jian [4 ]
Wang, Minghua [1 ]
Li, Qiong [1 ]
Ji, Sibei [1 ]
Li, Shaomin [5 ]
机构
[1] Xinxiang Med Univ, Affiliated Hosp 1, Henan Joint Int Res Lab Neurorestoratol Senile De, Henan Key Lab Neurorestoratol,Dept Neurol, Xinxiang 453100, Henan, Peoples R China
[2] Jianghan Univ, Hosp Wuhan 6, Dept Neurol, Affiliated Hosp, Wuhan 430015, Hubei, Peoples R China
[3] Xinxiang Med Univ, Dept Med Record Management, Affiliated Hosp 1, Xinxiang 453100, Henan, Peoples R China
[4] Xinxiang Med Univ, Dept Imaging, Affiliated Hosp 1, Xinxiang 453100, Henan, Peoples R China
[5] Harvard Med Sch, Brigham & Womens Hosp, Ann Romney Ctr Neurol Dis, Boston, MA 02115 USA
关键词
ischemic stroke; post-stroke cognitive impairment or dementia (PSCID); matrix metalloprotenase 9; genetic polymorphism; cognitive function; METALLOPROTEINASE GENE POLYMORPHISMS; MATRIX METALLOPROTEINASES; HARMONIZATION STANDARDS; CEREBROSPINAL-FLUID; BRAIN; STROKE; DISEASE; INFLAMMATION; DYSFUNCTION; DISORDERS;
D O I
10.31083/j.jin2106160
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Background: Matrix metalloproteinase-9 (MMP-9) is a significant protease required for synaptic plasticity, learning, and memory. Yet, the role of MMP-9 in the occurrence and development of cognitive decline after ischemic stroke is not fully understood. In this study, we used clinical data experiments to further investigate whether MMP-9 and genetic polymorphism are associated with poststroke cognitive impairment or dementia (PSCID). Materials and Methods: A total of 148 patients with PSCID confirmed by the Montreal Cognitive Assessment (MoCA) 3 months after onset (PSCID group) were included in the study. The MMP-9 rs3918242 polymorphisms were analyzed using polymerase chain reaction coupled with restriction fragment length polymorphism, and the serum level of MMP-9 was measured using enzyme-linked immunosorbent assay (ELISA). The same manipulations have been done on 169 ischemic stroke patients without cognitive impairment (NCI group) and 150 normal controls (NC group). Results: The expression level of serum MMP-9 in the PSCID group and NCI group was higher compared to the NC group, and the levels in the PSCID group were higher than that in the NCI group (all p < 0.05). Diabetes mellitus, hyperhomocysteinemia, and increased serum MMP-9 levels were the main risk factors of cognitive impairment after ischemic stroke. The serum level of MMP-9 was negatively correlated with the MoCA score, including visual-spatial executive, naming, attention, language, and delayed recall. Genetic polymorphism showed that TC genotype with MMP-9 rs3918242 and CC genotype were associated with a significantly increased risk of PSCID; moreover, the TC genotype significantly increased the risk of cognitive impairment. In the TCCC genotype of MMP-9 rs3918242, diabetes mellitus and hyperhomocysteinemia were associated with the increased risk of PSCID; also, hyperhomocysteinemia could increase the risk of cognitive impairment. Conclusions: MMP-9 level and MMP-9 rs3918242 polymorphism have an important role in the occurrence and development of post-stroke cognitive impairment or dementia (PSCID).
引用
收藏
页数:8
相关论文
共 55 条
  • [41] MMP-9 gene rs3918242 polymorphism increases risk of stroke: A meta-analysis
    Wang, Baohua
    Wang, Yinhua
    Zhao, Lei
    [J]. JOURNAL OF CELLULAR BIOCHEMISTRY, 2018, 119 (12) : 9801 - 9808
  • [42] Wang YK, 2019, INT J CLIN EXP PATHO, V12, P949
  • [43] Matrix Metalloproteinase in Blood-Brain Barrier Breakdown in Dementia
    Weekman, Erica M.
    Wilcock, Donna M.
    [J]. JOURNAL OF ALZHEIMERS DISEASE, 2016, 49 (04) : 893 - 903
  • [44] Association Between Matrix Metalloproteinase Family Gene Polymorphisms and Ischemic Stroke: a Meta-analysis
    Wen, Dan
    Du, Xin
    Nie, Shao-Ping
    Dong, Jian-Zeng
    Ma, Chang-Sheng
    [J]. MOLECULAR NEUROBIOLOGY, 2014, 50 (03) : 979 - 985
  • [45] Matrix metalloproteinases as therapeutic targets for stroke
    Yang, Yi
    Rosenberg, Gary A.
    [J]. BRAIN RESEARCH, 2015, 1623 : 30 - 38
  • [46] Cognitive Impairment Evaluated With Vascular Cognitive Impairment Harmonization Standards in a Multicenter Prospective Stroke Cohort in Korea
    Yu, Kyung-Ho
    Cho, Soo-Jin
    Oh, Mi Sun
    Jung, San
    Lee, Ju-Hun
    Shin, Joon-Hyun
    Koh, Im-Suck
    Cha, Jae-Kwan
    Park, Jong-Moo
    Bae, Hee-Joon
    Kang, Yeonwook
    Lee, Byung-Chul
    [J]. STROKE, 2013, 44 (03) : 786 - +
  • [47] Cerebral small vessel disease and vascular cognitive impairment: from diagnosis to management
    Zanon Zotin, Maria Clara
    Sveikata, Lukas
    Viswanathan, Anand
    Yilmaz, Pinar
    [J]. CURRENT OPINION IN NEUROLOGY, 2021, 34 (02) : 246 - 257
  • [48] Cerebral mast cells contribute to postoperative cognitive dysfunction by promoting blood brain barrier disruption
    Zhang, Susu
    Dong, Hongquan
    Zhang, Xiang
    Li, Nana
    Sun, Jie
    Qian, Yanning
    [J]. BEHAVIOURAL BRAIN RESEARCH, 2016, 298 : 158 - 166
  • [49] Temporal analysis of blood-brain barrier disruption and cerebrospinal fluid matrix metalloproteinases in rhesus monkeys subjected to transient ischemic stroke
    Zhang, Yingqian
    Fan, Feng
    Zeng, Guojun
    Zhou, Linlin
    Zhang, Yinbing
    Zhang, Jie
    Jiao, He
    Zhang, Ting
    Su, Dan
    Yang, Cheng
    Wang, Xin
    Xiao, Kai
    Li, Hongxia
    Zhong, Zhihui
    [J]. JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM, 2017, 37 (08) : 2963 - 2974
  • [50] Zhao JH, 2015, GENET MOL RES, V14, P19418, DOI 10.4238/2015.December.30.3